Summary
Global Markets Direct’s, ‘Hepatic Encephalopathy - Pipeline Review, H2 2016’, provides an overview of the Hepatic Encephalopathy pipeline landscape.
The report provides comprehensive information on the therapeutics under development for Hepatic Encephalopathy, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Hepatic Encephalopathy and features dormant and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.
Scope
- The report provides a snapshot of the global therapeutic landscape of Hepatic Encephalopathy
- The report reviews pipeline therapeutics for Hepatic Encephalopathy by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Hepatic Encephalopathy therapeutics and enlists all their major and minor projects
- The report assesses Hepatic Encephalopathy therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Hepatic Encephalopathy
Reasons to buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Hepatic Encephalopathy
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Hepatic Encephalopathy pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Companies Mentioned
Alfa Wassermann S.p.A
Cosmo Pharmaceuticals S.p.A
Horizon Pharma Plc
KannaLife Sciences, Inc.
Ocera Therapeutics, Inc.
Rebiotix Inc.
Spherium Biomed S.L.
Umecrine Cognition AB
'
Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Hepatic Encephalopathy Overview 7
Therapeutics Development 8
Pipeline Products for Hepatic Encephalopathy - Overview 8
Hepatic Encephalopathy - Therapeutics under Development by Companies 9
Hepatic Encephalopathy - Pipeline Products Glance 10
Late Stage Products 10
Clinical Stage Products 11
Early Stage Products 12
Unknown Stage Products 13
Hepatic Encephalopathy - Products under Development by Companies 14
Hepatic Encephalopathy - Companies Involved in Therapeutics Development 15
Alfa Wassermann S.p.A 15
Cosmo Pharmaceuticals S.p.A 16
Horizon Pharma Plc 17
KannaLife Sciences, Inc. 18
Ocera Therapeutics, Inc. 19
Rebiotix Inc. 20
Spherium Biomed S.L. 21
Umecrine Cognition AB 22
Hepatic Encephalopathy - Therapeutics Assessment 23
Assessment by Monotherapy Products 23
Assessment by Target 24
Assessment by Mechanism of Action 26
Assessment by Route of Administration 28
Assessment by Molecule Type 30
Drug Profiles 32
glycerol phenylbutyrate - Drug Profile 32
Product Description 32
Mechanism Of Action 32
R&D Progress 32
GR-3027 - Drug Profile 37
Product Description 37
Mechanism Of Action 37
R&D Progress 37
KLS-13019 - Drug Profile 38
Product Description 38
Mechanism Of Action 38
R&D Progress 38
ornithine phenylacetate - Drug Profile 39
Product Description 39
Mechanism Of Action 39
R&D Progress 39
RBX-2477 - Drug Profile 44
Product Description 44
Mechanism Of Action 44
R&D Progress 44
rifamycin CR - Drug Profile 45
Product Description 45
Mechanism Of Action 45
R&D Progress 45
rifaximin - Drug Profile 47
Product Description 47
Mechanism Of Action 47
R&D Progress 47
THDP-17 - Drug Profile 51
Product Description 51
Mechanism Of Action 51
R&D Progress 51
Hepatic Encephalopathy - Dormant Projects 52
Hepatic Encephalopathy - Product Development Milestones 53
Featured News & Press Releases 53
Apr 15, 2016: Ocera Therapeutics Announces Presentation of Two Preclinical Studies Further Supporting Its Ammonia Scavenger OCR-002 at The International Liver Congress 2016 of the European Association for the Study of the Liver (EASL) 53
Apr 11, 2016: Ocera Therapeutics Announces Publication of Promising Preclinical Data in Support of Its Ammonia Scavenger OCR-002 in the Journal of Hepatology 54
Jan 08, 2016: Ocera Announces Complete Plasma Data From Pilot Phase 1 Study for Orally-Available OCR-002 in Development for the Prevention of Chronic Hepatic Encephalopathy 54
Dec 09, 2015: Umecrine Cognition Announces Grant Of a US Patent Protecting Its Lead Candidate Drug GR3027 55
Nov 16, 2015: Ocera Announces Positive Phase 1 Results for Oral OCR-002 in Development for the Prevention of Chronic Hepatic Encephalopathy 56
Sep 16, 2015: Ocera Initiates Phase 1 Clinical Trial of Oral Drug Candidate OCR-002 for Prevention of Hepatic Encephalopathy 57
Aug 19, 2015: Umecrine Cognition announces the publication of preclinical results of the candidate drug GR3027 aimed for the treatment of hepatic encephalopathy 58
Aug 11, 2015: Kannalife Sciences Discusses Orphan Drug Opportunity for KLS-13019 58
Apr 20, 2015: Lupin Launches Zaxine in Canada 59
Apr 01, 2015: Ocera Completes Interim Analysis of OCR-002 in Phase 2b STOP-HE Study for the Treatment of Acute Hepatic Encephalopathy 59
Sep 18, 2014: Salix Secures Additional Intellectual Property Relating to Rifaximin 60
Sep 12, 2014: Lupin and Salix Announce Exclusive Distribution Agreement for Zaxine in Canada 60
Feb 25, 2014: Hyperion Therapeutics Announces the Publication of Phase 2 Results of Glycerol Phenylbutyrate for the Treatment of Hepatic Encephalopathy in Hepatology 61
Feb 14, 2014: Luxembourg National Health Fund Approves Reimbursement Of Xifaxan 550 61
Feb 04, 2014: Salix Pharmaceuticals Announces Issuance Of U. S. Patent For Rifaximin 62
Appendix 63
Methodology 63
Coverage 63
Secondary Research 63
Primary Research 63
Expert Panel Validation 63
Contact Us 63
Disclaimer 64
List of Tables
Number of Products under Development for Hepatic Encephalopathy, H2 2016 8
Number of Products under Development by Companies, H2 2016 9
Comparative Analysis by Late Stage Development, H2 2016 10
Comparative Analysis by Clinical Stage Development, H2 2016 11
Comparative Analysis by Early Stage Development, H2 2016 12
Comparative Analysis by Unknown Stage Development, H2 2016 13
Products under Development by Companies, H2 2016 14
Hepatic Encephalopathy - Pipeline by Alfa Wassermann S.p.A, H2 2016 15
Hepatic Encephalopathy - Pipeline by Cosmo Pharmaceuticals S.p.A, H2 2016 16
Hepatic Encephalopathy - Pipeline by Horizon Pharma Plc, H2 2016 17
Hepatic Encephalopathy - Pipeline by KannaLife Sciences, Inc., H2 2016 18
Hepatic Encephalopathy - Pipeline by Ocera Therapeutics, Inc., H2 2016 19
Hepatic Encephalopathy - Pipeline by Rebiotix Inc., H2 2016 20
Hepatic Encephalopathy - Pipeline by Spherium Biomed S.L., H2 2016 21
Hepatic Encephalopathy - Pipeline by Umecrine Cognition AB, H2 2016 22
Assessment by Monotherapy Products, H2 2016 23
Number of Products by Stage and Target, H2 2016 25
Number of Products by Stage and Mechanism of Action, H2 2016 27
Number of Products by Stage and Route of Administration, H2 2016 29
Number of Products by Stage and Molecule Type, H2 2016 31
Hepatic Encephalopathy - Dormant Projects, H2 2016 52
List of Figures
Number of Products under Development for Hepatic Encephalopathy, H2 2016 8
Number of Products under Development by Companies, H2 2016 9
Comparative Analysis by Clinical Stage Development, H2 2016 11
Assessment by Monotherapy Products, H2 2016 23
Number of Products by Targets, H2 2016 24
Number of Products by Stage and Targets, H2 2016 24
Number of Products by Mechanism of Actions, H2 2016 26
Number of Products by Stage and Mechanism of Actions, H2 2016 26
Number of Products by Routes of Administration, H2 2016 28
Number of Products by Stage and Routes of Administration, H2 2016 28
Number of Products by Molecule Types, H2 2016 30
Number of Products by Stage and Molecule Types, H2 2016 30
